Saturday 17 October 2026
Export JAZZ’s income statement to Excel — free account
Jazz Pharmaceuticals PLC
JAZZ Healthcare Biotechnology
Jazz Pharmaceuticals PLC’s revenue for fiscal 2025 (year ended December 2025) was $4.3 billion, up 4.88% from fiscal 2024. In the quarter to June 2026, revenue grew 15.6%, EPS grew 126.0%, free cash flow grew 141.0% and total debt fell 18.9%, each against the same quarter a year earlier. Revenue growth for ten consecutive years.
210.05
4.37
−2.04%
Follow JAZZ
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
17.31 | 16.90 | 16.62 | 16.19 | 38.29 | 0.00 | 0.00 | 19.38 | 13.52 | 0.00 |
Piotroski F-Score |
5 | 8 | 8 | 9 | 4 | 2 | 4 | 7 | 8 | 5 |
P/S ratio |
4.53 | 5.09 | 3.93 | 3.92 | 3.89 | 2.46 | 2.67 | 2.10 | 1.87 | 2.43 |
Altman Z-Score |
2.35 | 3.08 | 3.01 | 3.35 | 3.12 | 1.12 | 1.37 | 1.42 | 1.60 | 1.37 |
P/FCF ratio |
16.49 | 14.24 | 10.51 | 13.93 | 17.67 | 10.38 | 12.64 | 7.66 | 5.65 | 32.79 |
Altman Z″-Score (non-manufacturers) |
2.53 | 3.32 | 3.63 | 4.12 | 4.50 | 1.77 | 1.61 | 2.20 | 3.21 | 1.63 |
Beneish M-Score |
(2.45) | (2.64) | (2.70) | (2.43) | (2.96) | (2.53) | (3.01) | (2.71) | (2.84) | (3.03) |
P/Operating CF |
37.32 | 40.31 | 34.09 | 96.49 | 49.37 | 42.78 | 28.59 | 48.01 | 19.11 | 28.60 |
P/B ratio |
3.59 | 3.04 | 2.70 | 2.72 | 2.51 | 1.92 | 3.17 | 2.15 | 1.86 | 2.40 |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | 18.16 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Sales |
5.61 | 5.70 | 4.34 | 4.16 | 3.87 | 4.22 | 4.00 | 3.16 | 2.64 | 3.11 |
EV/EBITDA |
11.47 | 12.74 | 9.37 | 9.97 | 13.95 | 18.07 | 25.93 | 9.96 | 7.79 | 49.93 |
EV/Operating CF |
14.09 | 13.31 | 10.27 | 11.59 | 10.18 | 16.78 | 11.50 | 11.10 | 7.69 | 9.80 |
EV/FCF |
20.41 | 15.93 | 11.60 | 14.80 | 17.60 | 17.82 | 18.90 | 11.55 | 7.96 | 42.02 |
Quick Ratio |
2.56 | 2.81 | 3.15 | 3.93 | 3.87 | 1.43 | 1.64 | 1.52 | 3.57 | 1.46 |
Current Ratio |
2.91 | 3.29 | 3.57 | 4.47 | 4.34 | 3.23 | 2.79 | 2.24 | 4.46 | 1.86 |
Net Debt/EBITDA |
2.20 | 1.35 | 0.88 | 0.59 | (0.06) | 7.55 | 8.59 | 3.36 | 2.26 | 10.96 |
Debt/Assets |
42.28% | 30.86% | 30.68% | 29.02% | 32.05% | 49.19% | 52.83% | 50.14% | 50.85% | 45.96% |
Debt/Equity |
1.08 | 0.58 | 0.58 | 0.52 | 0.57 | 1.53 | 1.86 | 1.53 | 1.49 | 1.24 |
Asset Turnover |
0.37 | 0.33 | 0.37 | 0.40 | 0.39 | 0.33 | 0.32 | 0.35 | 0.35 | 0.36 |
Operating CF/Net income |
1.49 | 1.42 | 1.79 | 1.48 | 3.77 | (2.36) | (5.68) | 2.48 | 2.45 | (3.81) |
Capex/Depreciation |
(1.35) | (0.58) | (0.32) | (0.45) | (1.36) | (0.08) | (0.79) | (0.07) | (0.07) | (1.49) |
Interest Coverage |
9.55 | 6.80 | 7.83 | 7.37 | 3.79 | 0.61 | (0.23) | 2.00 | 3.01 | (2.21) |
| 22.83% | 21.25% | 16.35% | 17.84% | 7.05% | (8.65%) | (6.36%) | 12.89% | 14.58% | (8.47%) | |
| 9.76% | 9.83% | 8.66% | 9.74% | 3.95% | (3.50%) | (1.94%) | 3.96% | 4.88% | (3.01%) | |
ROIC |
10.62% | 8.95% | 10.89% | 9.14% | 6.52% | 1.13% | (0.52%) | 4.62% | 6.21% | (3.72%) |
Return on Tangible Assets |
66.34% | 57.77% | 41.06% | 37.46% | 10.31% | (16.01%) | (11.79%) | 21.26% | 15.17% | (16.77%) |
Average Days of Receivables |
57.46 | 50.54 | 50.93 | 60.11 | 61.23 | 66.45 | 64.98 | 67.19 | 64.30 | 71.05 |
Research and Development Expense of Revenue |
10.91% | 12.26% | 11.98% | 13.86% | 14.19% | 16.34% | 16.14% | 22.16% | 21.73% | 18.34% |
Selling, General and Administrative Expense of Revenue |
33.80% | 33.62% | 36.15% | 34.09% | 36.14% | 46.92% | 38.72% | 35.03% | 34.05% | 42.40% |
Intangible Assets out of Total Assets |
0.81 | 0.77 | 0.70 | 0.61 | 0.48 | 0.73 | 0.69 | 0.63 | 0.54 | 0.54 |
Share Based Compensation of Revenue |
6.64% | 6.60% | 5.42% | 5.11% | 5.12% | 6.11% | 6.07% | 5.92% | 6.10% | 6.82% |
Graham Net Nets |
(0.32) | (0.17) | (0.16) | (0.09) | 0.00 | (0.75) | (0.53) | (0.53) | (0.43) | (0.31) |
Graham Number |
67.05 | 90.93 | 87.85 | 106.64 | 79.81 | 0.00 | 0.00 | 93.28 | 116.49 | 0.00 |
Earnings Yield |
5.78% | 5.92% | 6.02% | 6.18% | 2.61% | (4.22%) | (2.26%) | 5.16% | 7.40% | (3.41%) |
Free Cash Flow Yield |
6.06% | 7.02% | 9.51% | 7.18% | 5.66% | 9.64% | 7.91% | 13.06% | 17.70% | 3.05% |
Revenue per Share |
24.59 | 26.97 | 31.53 | 38.09 | 42.42 | 51.84 | 58.51 | 60.58 | 65.80 | 69.98 |
Operating CF per Share |
9.79 | 11.55 | 13.32 | 13.68 | 16.15 | 13.04 | 20.34 | 17.25 | 22.57 | 22.23 |
Capex per Share |
(3.03) | (1.90) | (1.39) | (2.96) | (6.81) | (0.76) | (7.97) | (0.68) | (0.78) | (17.05) |
Free Cash Flow per Share |
6.76 | 9.65 | 11.93 | 10.72 | 9.34 | 12.28 | 12.37 | 16.57 | 21.80 | 5.18 |
Cash per Share |
7.04 | 10.01 | 13.75 | 18.98 | 38.28 | 9.91 | 14.09 | 25.70 | 48.40 | 40.04 |
Shareholders Equity per Share |
31.03 | 45.20 | 45.98 | 54.82 | 65.69 | 66.43 | 49.34 | 59.04 | 66.20 | 70.82 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
31.03 | 45.20 | 45.98 | 54.82 | 65.69 | 66.43 | 49.34 | 59.04 | 66.20 | 70.82 |
Free Cash Flow |
408.95 | 579.14 | 715.33 | 608.28 | 520.39 | 732.98 | 773.78 | 1,049.05 | 1,347.84 | 316.14 |
Working Capital |
490.66 | 674.33 | 888.52 | 1,265.78 | 2,185.82 | 1,802.03 | 1,672.95 | 1,898.74 | 3,590.46 | 1,923.52 |
Capital Expenditures |
(183.44) | (113.95) | (83.57) | (168.13) | (379.25) | (45.53) | (498.19) | (42.96) | (48.07) | (1,039.64) |
Net Current Asset Value |
(2,174.82) | (1,442.30) | (1,212.06) | (797.65) | (36.59) | (5,722.11) | (5,143.38) | (4,220.93) | (3,289.48) | (3,174.71) |
EV/EBIT |
14.11 | 17.45 | 13.35 | 16.91 | 24.22 | 76.72 | 0.00 | 20.95 | 14.97 | 0.00 |
Capex to Sales |
0.12 | 0.07 | 0.04 | 0.08 | 0.16 | 0.01 | 0.14 | 0.01 | 0.01 | 0.24 |
Price to Operating Income |
11.40 | 15.59 | 12.09 | 15.91 | 24.32 | 44.66 | 0.00 | 13.88 | 10.63 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
1.26 | 1.15 | 1.30 | 2.81 | 2.18 | 2.15 | 2.76 | 3.76 | 3.81 | 3.48 |
Cash ROIC |
9.44% | 11.83% | 13.81% | 10.50% | 6.60% | 6.91% | 7.98% | 9.47% | 10.21% | 2.61% |
Accounts Receivable Turnover |
6.70 | 7.06 | 7.75 | 6.98 | 6.28 | 6.45 | 6.02 | 5.65 | 5.72 | 5.52 |
Accounts Payable Turnover |
4.77 | 4.71 | 3.74 | 2.96 | 4.10 | 6.93 | 5.66 | 4.50 | 4.94 | 5.03 |
Inventory Turnover |
3.94 | 2.85 | 2.53 | 1.94 | 1.71 | 0.75 | 0.61 | 0.66 | 0.83 | 1.12 |
Average Days of Payables |
77.63 | 80.72 | 121.93 | 130.48 | 66.04 | 83.06 | 61.29 | 86.10 | 63.77 | 88.52 |
Days of Inventory on Hand |
117.93 | 143.25 | 159.03 | 224.28 | 233.82 | 888.34 | 482.19 | 500.30 | 393.44 | 302.39 |
Average Receivables |
221.96 | 229.19 | 243.98 | 309.91 | 376.24 | 479.93 | 607.43 | 678.64 | 711.28 | 773.76 |
Average Payables |
22.11 | 23.39 | 32.49 | 43.17 | 36.34 | 63.62 | 95.53 | 96.75 | 90.31 | 99.97 |
Average Inventory |
26.75 | 38.65 | 48.10 | 65.78 | 87.00 | 584.06 | 893.39 | 655.55 | 538.74 | 448.70 |
Average Assets |
4,066.42 | 4,961.95 | 5,163.58 | 5,371.19 | 6,037.40 | 9,417.27 | 11,566.95 | 11,114.31 | 11,702.81 | 11,835.80 |
Average Common Equity |
1,737.99 | 2,295.22 | 2,735.26 | 2,934.20 | 3,385.36 | 3,812.47 | 3,525.46 | 3,411.37 | 3,915.38 | 4,206.17 |
Columns are period end dates